[A13-25] Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 16.09.2013
Project no.:
A13-25
Commission:
Commission awarded on 14.06.2013 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-59 | Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |
Federal Joint Committee (G-BA)
2013-12-05 A G-BA decision was published.